Trial Search Results
Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
The investigators will enroll a total of 628 patients under 18 years of age with ARP or CP. Included in the total are the 357patients in the INSPPIRE 1 database who are planned to be reenrolled under this protocol over the next 4 years. Patient questionnaires and physician surveys will be applied at the time of enrollment and annually thereafter as long as possible. At the first study visit after turning 18 years of age, the patient will sign the informed consent to continue in the study. Specifically, the investigators will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
Stanford is currently accepting patients for this trial.
Collaborator: National Cancer Institute (NCI)
- Diagnostic Test: Blood sample
- Behavioral: Patient questionnaires
- Diagnostic Test: Saliva sample
- Diagnostic Test: Urine sample
1. All patients/parents must sign an informed consent and/or assent indicating that they
are aware of the investigational nature of this study.
2 Patients/parents must have signed an authorization for the release of their or their
child's protected health information.
3 All children providing samples should fit the ARP or CP inclusion criteria defined below.
4 All children must be under 18 years of age at the time of enrollment.
Acute pancreatitis (AP): AP is defined as requiring 2 of the following:
1. Abdominal pain compatible with AP,
2. Serum amylase and/or lipase values ≥3 times upper limits of normal,
3. Imaging findings of AP, such as gland enlargement, acute inflammatory changes, and
ARP is defined as:
At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month
pain-free interval between episodes.
Children with at least:
1. One irreversible structural change* in the pancreas with or without abdominal pain +/-
exocrine pancreatic insufficiency +/- diabetes.
*irreversible structural changes:
- Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging
(abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance
cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic
retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).
- Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2
months) on any imaging.
- Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities
alone are not diagnostic findings for CP.
- Surgical or pancreatic biopsy specimen demonstrating histopathologic features
compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with
lymphocytes, plasma cells, macrophages).
- Patients must not have any significant medical illnesses that in the investigator's
opinion cannot be adequately controlled with appropriate therapy or would compromise
the patient's ability to tolerate study interventions.
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study